nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Activating KIR: iN Kase of KIR-ligand mismatch
|
Shah, Nina |
|
|
125 |
20 |
p. 3045-3046 |
artikel |
2 |
Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans
|
Nakasone, Hideki |
|
|
125 |
20 |
p. 3193-3201 |
artikel |
3 |
Cellular fibronectin containing extra domain A promotes arterial thrombosis in mice through platelet Toll-like receptor 4
|
Prakash, Prem |
|
|
125 |
20 |
p. 3164-3172 |
artikel |
4 |
Editorial Board
|
|
|
|
125 |
20 |
p. i |
artikel |
5 |
Endothelial cells suppress monocyte activation through secretion of extracellular vesicles containing antiinflammatory microRNAs
|
Njock, Makon-Sébastien |
|
|
125 |
20 |
p. 3202-3212 |
artikel |
6 |
Fibronectin: extra domain brings extra risk?
|
Wang, Yiming |
|
|
125 |
20 |
p. 3043-3044 |
artikel |
7 |
Frontline therapy of multiple myeloma
|
Moreau, Philippe |
|
|
125 |
20 |
p. 3076-3084 |
artikel |
8 |
Granulocyte colony-stimulating factor reprograms bone marrow stromal cells to actively suppress B lymphopoiesis in mice
|
Day, Ryan B. |
|
|
125 |
20 |
p. 3114-3117 |
artikel |
9 |
Haploidentical hematopoietic transplantation from KIR ligand–mismatched donors with activating KIRs reduces nonrelapse mortality
|
Mancusi, Antonella |
|
|
125 |
20 |
p. 3173-3182 |
artikel |
10 |
HY antibodies as biomarkers for chronic GVHD
|
Mutis, Tuna |
|
|
125 |
20 |
p. 3046-3047 |
artikel |
11 |
Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach
|
Nonami, Atsushi |
|
|
125 |
20 |
p. 3133-3143 |
artikel |
12 |
IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells
|
Schinke, Carolina |
|
|
125 |
20 |
p. 3144-3152 |
artikel |
13 |
Introduction to a series of reviews on multiple myeloma
|
San Miguel, Jesús F. |
|
|
125 |
20 |
p. 3039-3040 |
artikel |
14 |
Lymphoma and gout coexisting in the same joint fluid
|
Arboleda, Valerie A. |
|
|
125 |
20 |
p. 3213 |
artikel |
15 |
New criteria for response assessment: role of minimal residual disease in multiple myeloma
|
Paiva, Bruno |
|
|
125 |
20 |
p. 3059-3068 |
artikel |
16 |
Pathogenesis beyond the cancer clone(s) in multiple myeloma
|
Bianchi, Giada |
|
|
125 |
20 |
p. 3049-3058 |
artikel |
17 |
Perivascular deletion of murine Rac reverses the ratio of marrow arterioles and sinusoid vessels and alters hematopoiesis in vivo
|
Ciuculescu, Marioara F. |
|
|
125 |
20 |
p. 3105-3113 |
artikel |
18 |
Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma
|
Moreau, Philippe |
|
|
125 |
20 |
p. 3100-3104 |
artikel |
19 |
Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia
|
Hing, Zachary A. |
|
|
125 |
20 |
p. 3128-3132 |
artikel |
20 |
Smoldering multiple myeloma
|
Rajkumar, S. Vincent |
|
|
125 |
20 |
p. 3069-3075 |
artikel |
21 |
Targets of opportunity for precision medicine
|
Saunthararajah, Yogen |
|
|
125 |
20 |
p. 3041-3042 |
artikel |
22 |
The IL-33/ST2 axis augments effector T-cell responses during acute GVHD
|
Reichenbach, Dawn K. |
|
|
125 |
20 |
p. 3183-3192 |
artikel |
23 |
The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphoma
|
Boddicker, Rebecca L. |
|
|
125 |
20 |
p. 3118-3127 |
artikel |
24 |
The tumor virus landscape of AIDS-related lymphomas
|
Arvey, Aaron |
|
|
125 |
20 |
p. e14-e22 |
artikel |
25 |
Treatment options for relapsed and refractory multiple myeloma
|
Nooka, Ajay K. |
|
|
125 |
20 |
p. 3085-3099 |
artikel |
26 |
von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans
|
Bauer, Alexander T. |
|
|
125 |
20 |
p. 3153-3163 |
artikel |
27 |
VWF fibers induce thrombosis during cancer
|
Borsig, Lubor |
|
|
125 |
20 |
p. 3042-3043 |
artikel |